1 / 6

Understanding GAVI's AMC: Innovative Financing for Pneumococcal Vaccines

GAVI's Advance Market Commitment (AMC) is a groundbreaking financing mechanism designed to ensure the availability of effective pneumococcal vaccines for developing countries. Donors pledge funds at predetermined prices, enabling manufacturers to invest in vaccine research and development. In return for upfront financing, manufacturers commit to supplying vaccines at reduced long-term prices, ensuring accessibility and affordability for beneficiary countries. This initiative aims to lower morbidity and mortality from pneumococcal diseases and accelerate the uptake of vital vaccines, delivering on public health goals.

kelton
Télécharger la présentation

Understanding GAVI's AMC: Innovative Financing for Pneumococcal Vaccines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Innovative financing GAVI/09/Olivier Asselin

  2. How AMC works • Donors commit funds to finance the purchase of new vaccines at a pre-agreed price for a certain amount of doses • These financial commitments provide the guarantee that manufacturers need to invest in the necessary research and development of the new vaccine. • Manufacturers can participate in the AMC if and when they develop a  vaccine that meets specific and stringent criteria and if the vaccine is requested by beneficiary countries • In exchange for the upfront donor funds, manufacturers legally commit to supply their vaccine at a lower price over the long-term. • The long-term price is paid by beneficiary countries and GAVI.

  3. The Pneumococcal AMC pilot • Overarching goal: reduce morbidity and mortality from pneumococcal diseases. • Main objectives: • Bring forward the availability of effective pneumococcal vaccines - scale up of production capacity. • Accelerate development of second generation vaccines that meet developing country needs. • Accelerate vaccine uptake - predictable vaccine pricing for countries and manufacturers. • Test AMC concept

  4. The pneumococcal AMC funding sources $7 AMCfunds AMC Price per Dose Tail price cap $3.50 GAVI funding Country Co-pay ( $0.10 - $0.30 per dose initially) * $0 2 4 6 8 10 Years 1stEligible Vaccine available supplier’s share of AMC funds depleted Supply Commitment Fulfilled 10 yrs * Co-financing levels will be in line with the applicable GAVI co-financing policy. Source: GAVI Alliance, 2009

  5. What does this mean for GAVI countries? Same • Countries express their preference on pneumococcal vaccines • GAVI co-financing and default policies will apply to the AMC without modifications • Vaccines are procured through UNICEF But different • Vaccines will be available in the right quantities to cover demand • Availability of support funding is known years in advance • The price of these vaccines for developing countries is known years before procurement starts

  6. Progress to date & next steps First call for offers September 4th, 2009 legal agreements signed on 12 June 2009 Vaccines could be delivered to countries 2010 SDF v 0.1 published 7th August, 2009 2010 2009 First Supply Agreement potentiallysigned Q1 2010 Design Implementation

More Related